18:49 , Oct 20, 2017 |  BioCentury  |  Regulation

Realities of real-world evidence

After countless conferences, white papers and speeches, stakeholders across the healthcare ecosystem are finally coming together to figure out how to extend the use of real-world evidence beyond pharmacovigilance and into drug development. The payoffs...
19:54 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Xarelto lowers CV risk, ups major bleeds in Phase III for artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban (BAY 59-7939) plus once-daily 100 mg...
22:59 , Aug 28, 2017 |  BC Extra  |  Clinical News

Xarelto lowers CV risk, ups major bleeds in artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) released full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban plus once-daily 100 mg aspirin reduced...
14:07 , Aug 23, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug properties

TECHNOLOGY: Cellular assays; toxicology A culture system for generating gut tubules could be used to screen drug compounds for adverse effects on the gut epithelial barrier. The method involves seeding human intestinal colorectal adenocarcinoma cells adjacent...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO’s call...
00:34 , Jun 30, 2017 |  BC Extra  |  Preclinical News

Hormone tied to treating preeclampsia

In a paper published in Science, researchers at Singapore's Agency for Science Technology and Research (A*STAR) show lack of a hormone normally secreted by the placenta in pregnant mice led to preeclampsia symptoms, and treatment...
18:32 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph III EINSTEIN CHOICE data

The double-blind, international Phase III EINSTEIN CHOICE trial in 3,365 patients with confirmed symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) who were initially treated with 6 or 12 months of anticoagulation therapy showed...
18:31 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph II GEMINI-ACS-1 data

The double-blind, international Phase II GEMINI-ACS-1 trial in 3,037 patients with ACS showed that twice-daily 2.5 mg oral Xarelto plus clopidogrel or Brilinta ticagrelor led to no significant difference in the rate of TIMI clinically...
21:20 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph III COMPASS data

Johnson & Johnson’s Janssen Research & Development LLC unit said the double-blind, placebo-controlled, international Phase III COMPASS trial evaluating oral Xarelto in 27,402 CAD or PAD patients was stopped early on the recommendation of an...
16:16 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Pradaxa: Completed Ph III enrollment

Boehringer completed enrollment of 2,727 patients in the open-label, international Phase III RE-DUAL PCI trial comparing 110 and 150 mg oral Pradaxa twice daily plus clopidogrel or Brilinta ticagrelor vs. triple antithrombotic therapy comprising warfarin,...